We retrospectively reviewed the real-world data of pyrotinib treatment in HER2-positive stage III/IV BC patients in clinical practice, supplementing the results of clinical trials and providing a reference for further exploration of pyrotinib treatment patterns. Here, ERBB2 is linked to breast cancer.